These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23063327)

  • 21. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment.
    Hirschtritt ME; Bloch MH; Mathews CA
    JAMA; 2017 Apr; 317(13):1358-1367. PubMed ID: 28384832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder.
    Pekrul SR; Fitzgerald KD
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):593-5. PubMed ID: 26258664
    [No Abstract]   [Full Text] [Related]  

  • 23. Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Sahraian A; Jahromi LR; Ghanizadeh A; Mowla A
    J Clin Psychopharmacol; 2017 Apr; 37(2):246-249. PubMed ID: 28099183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
    Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
    Rodriguez CI; Kegeles LS; Levinson A; Feng T; Marcus SM; Vermes D; Flood P; Simpson HB
    Neuropsychopharmacology; 2013 Nov; 38(12):2475-83. PubMed ID: 23783065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.
    Rodriguez CI; Levinson A; Zwerling J; Vermes D; Simpson HB
    J Clin Psychiatry; 2016 May; 77(5):688-9. PubMed ID: 27249077
    [No Abstract]   [Full Text] [Related]  

  • 27. A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life.
    Strzelecki D; Tabaszewska A; Barszcz Z; Józefowicz O; Kropiwnicki P; Rabe-Jabłońska J
    Psychiatry Investig; 2013 Dec; 10(4):421-4. PubMed ID: 24474993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation strategies in obsessive-compulsive disorder.
    Arumugham SS; Reddy JY
    Expert Rev Neurother; 2013 Feb; 13(2):187-202; quiz 203. PubMed ID: 23368806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.
    M Koran L; Aboujaoude E
    Curr Med Chem; 2018; 25(41):5690-5697. PubMed ID: 28552055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating OCD: what to do when first-line therapies fail.
    Castle D; Bosanac P; Rossell S
    Australas Psychiatry; 2015 Aug; 23(4):350-3. PubMed ID: 26104775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study.
    Emamzadehfard S; Kamaloo A; Paydary K; Ahmadipour A; Zeinoddini A; Ghaleiha A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):332-41. PubMed ID: 27106362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study.
    Amidfar M; Khiabany M; Kohi A; Salardini E; Arbabi M; Roohi Azizi M; Zarrindast MR; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    J Clin Pharm Ther; 2017 Feb; 42(1):44-50. PubMed ID: 27809351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder.
    Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang YS; Wang LJ; Lee IH; Yeh TL; Yang YK; Lu RB; Hong JS
    J Psychiatr Res; 2013 Oct; 47(10):1343-8. PubMed ID: 23870798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
    Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
    Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmentation With Memantine in Obsessive-Compulsive Disorder.
    Andrade C
    J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
    Farnia V; Gharehbaghi H; Alikhani M; Almasi A; Golshani S; Tatari F; Davarinejad O; Salemi S; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    J Psychiatr Res; 2018 Sep; 104():137-143. PubMed ID: 30044966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder.
    Grassi G; Cecchelli C; Vignozzi L; Pacini S
    J Exp Pharmacol; 2020; 12():695-706. PubMed ID: 33447096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
    Del Casale A; Sorice S; Padovano A; Simmaco M; Ferracuti S; Lamis DA; Rapinesi C; Sani G; Girardi P; Kotzalidis GD; Pompili M
    Curr Neuropharmacol; 2019; 17(8):710-736. PubMed ID: 30101713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis.
    Zhou DD; Zhou XX; Li Y; Zhang KF; Lv Z; Chen XR; Wan LY; Wang W; Wang GM; Li DQ; Ai M; Kuang L
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():277-287. PubMed ID: 30576763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.